Overall survival | Disease-free survival | |||||
---|---|---|---|---|---|---|
Variables | HR | CI95% | P-value | HR | CI95% | P-value |
FBL | ||||||
Intermediate | 1.00 | 0.0230* | 1.00 | 0.0149* | ||
Low | 2.16 | [1.24–3.74] | 2.02 | [1.21–3.39] | ||
High | 1.32 | [0.74–2.34] | 1.56 | [0.94–2.56] | ||
NOP58 | ||||||
Low | 1.00 | 0.4034 | 1.00 | 0.3036 | ||
High | 1.27 | [0.73–2.22] | 1.32 | [0.78–2.24] | ||
Tumor size | ||||||
< 30 mm | 1.00 | < 0.0001*** | 1.00 | 0.0004** | ||
≥ 30 mm | 2.70 | [1.71–4.23] | 2.07 | [1.38–3.09] | ||
Lymph node invasion status | ||||||
N = 0 | 1.00 | 0.0386* | 1.00 | 0.0180* | ||
N ≥ 1 | 1.63 | [1.02–2.60] | 1.64 | [1.09–2.47] | ||
Breast cancer subtypes | ||||||
ER + PR ± HER2- | 1.00 | 0.0616 | N/A | N/A | ||
ER ± PR ± HER2 + | 1.05 | [0.62–1.76] | ||||
ER- PR- HER2- | 1.88 | [1.08–3.26] |